Pharmaceuticals, Biotechnology and Life Sciences
Basilea Pharmaceutica has named Adesh Kaul as its Management Committee’s Chief Corporate Development Officer, who has been leading partnering activities…
Basilea Pharmaceutica’s revenue in 2017 increased to CHF 101.5 million fromCHF 66.0 million in 2016, which represents an increase of…
Basilea Pharmaceutica has entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CR Gosun) for Basilea’s antibiotic Zevtera (ceftobiprole) in China, Hong Kong and Macao (the Territory).
Basilea Pharmaceutica’s Basilea Pharmaceutica International Ltd. has entered into a distribution agreement with Cardiome Pharma Corp. for Basilea’s antibiotic Zevtera/Mabelio (ceftobiprole) in Europe (excluding Nordic countries) and Israel.